{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-021971","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.995289+00:00","generated_at":"2026-06-02T05:53:38.411225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track","bullets":["Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.","Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.","Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.","IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.","Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-021971","json":"https://secwatch.observer/filing/0001628280-24-021971.json","markdown":"https://secwatch.observer/filing/0001628280-24-021971.md","text":"https://secwatch.observer/filing/0001628280-24-021971.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/mnlo-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:53:38.411225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dfb67ce79655a5911c95ff28b00e79c4d184eee8","claim":"VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.","evidence_excerpt":"financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1566044/000162828024021971/0001628280-24-021971-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.1 million"},{"label":"Net income","value":"$6.2 million"},{"label":"EPS","value":"$0.15"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}